POLICY: Hematology – Corifact® (Factor XIII Concentrate [human] injection for intravenous use – CSL Behring)

APPROVAL DATE: 09/11/2019

OVERVIEW
Cortifact, a Factor XIII concentrate, is indicated for routine prophylactic treatment and perioperative management of surgical bleeding in adult and pediatric patients with congenital Factor XIII deficiency.¹

Disease Overview
Congenital Factor XIII deficiency is caused by defects in both Factor XIIIA and Factor XIIIB genes.²⁻⁵ However, most cases are due to genetic alterations on the Factor XIIIA gene. The estimated prevalence of Factor XIIIA deficiency is one in 2 million patients. Clinical symptoms include delayed wound healing, bleeding of soft and subcutaneous tissue, recurrent spontaneous miscarriage, and central nervous system (CNS) bleeding, which may be life-threatening. If patients have severe Factor XIII deficiency, early manifestations include bleeding from the umbilical cord or CNS. Prospective data showed that a level of 30% Factor XIII clotting activity is an adequate therapeutic target for most patients. Treatment of Factor XIII deficiency involves use of fresh frozen plasma, cryoprecipitate, Corifact, or Tretten® (coagulation Factor XIIIA-Subunit [recombinant] injection for intravenous use).

Guidelines
The National Hemophilia Foundation Medical and Scientific Advisory Council has guidelines for the treatment of hemophilia and other bleeding disorders (revised April 2018).⁶ Corifact is recommended in patients who have Factor XIII deficiency.

Dosing Considerations
Dosing of clotting factor concentrates is highly individualized. MASAC provides recommendations regarding doses of clotting factor concentrate in the home (2016).⁷ The number of required doses varies greatly and is dependent on the severity of the disorder and the prescribed regimen. Per MASAC guidance, patients on prophylaxis should also have a minimum of one major dose and two minor doses on hand for breakthrough bleeding in addition to the prophylactic doses used monthly. The guidance also notes that an adequate supply of clotting factor concentrate is needed to accommodate weekends and holidays. Therefore, maximum doses in this policy allow for prophylactic dosing plus three days of acute bleeding or perioperative management per 28 days. Doses exceeding this quantity will be reviewed on a case-by-case basis by a clinician.

POLICY STATEMENT
Prior authorization is recommended for medical benefit coverage Corifact. Approval is recommended for those who meet the Criteria and Dosing for the listed indication(s). Extended approvals are allowed if the patient continues to meet the criteria and dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). Because of the specialized skills required for evaluation and diagnosis of patients treated with Corifact, as well as the monitoring required for adverse events and long-term efficacy, the agent is required to be prescribed by or in consultation with a physician who specializes in the condition being treated.

RECOMMENDED AUTHORIZATION CRITERIA
Coverage of Corifact is recommended for patients who meet criteria:
FDA-Approved Indication

1. **Congenital Factor XIII Deficiency.** Approve for 1 year if the agent is prescribed by or in consultation with a hematologist.

   **Dosing.** Approve up to 160 IU/kg by intravenous infusion no more frequently than once every 28 days.

**CONDITIONS NOT RECOMMENDED FOR APPROVAL**

1. **Other Indications.** Coverage is not recommended for circumstances not listed in the Authorization Criteria. Criteria will be updated as new published data are available.

**REFERENCES**


**HISTORY**

<table>
<thead>
<tr>
<th>Type of Revision</th>
<th>Summary of Changes</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>New policy</td>
<td>--</td>
<td>09/11/2019</td>
</tr>
</tbody>
</table>